Latest news with #OBIO
National Post
a day ago
- Health
- National Post
OBIO® Supports A4i to Expand Canadian Presence Through New Partnership With Waypoint Centre for Mental Health Care
Article content TORONTO — Among patients with complex behavioural and mental health conditions, 23% face re-hospitalization within 30 days of discharge and 75% stop taking their medications after 18 months. Patient populations with severe mental illness require high patient engagement and support. To address this issue, A4i (App4Independence) offers patients an opportunity to play an active role in their care via a mobile application, promoting greater autonomy. Additionally, A4i's clinical portal provides their care team with the necessary insights to identify the risk of a relapse, allowing for earlier intervention. Article content With funding support from OBIO's Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence to adopt and implement the technology, A4i has secured a contract with the Waypoint Centre for Mental Health Care, one of Ontario's most highly specialized mental health facilities, which offers a range of mental health and addiction services, including specialized care for individuals living with severe mental illness. This partnership is a key milestone for A4i, as it advances commercialization and ROI demonstration in the Canadian healthcare landscape. Article content In 2024, A4i completed a successful evaluation at the Royal Ottawa Health Centre through OBIO's Early Adopter Health Network (EAHN™), making the technology available for wider dissemination among network healthcare organizations interested in acquiring A4i. With this partnership, A4i is broadening the adoption of its digital platform in Canada, expanding its commercialization with hospital partners in the province of Ontario. Article content 'By empowering people with the tools to manage their care, while giving clinicians meaningful, real-time insight, we're solving real-world challenges to improve continuity of care, reducing relapse risk, and supporting recovery beyond the walls of the hospital,' said Amos Adler, Co-Founder of A4i and CEO of MEMOTEXT. Article content The implementation of the A4i technology at Waypoint will be driven by A4i's 'health at home' initiative. As Waypoint covers a large geographical area, much of which is rural, patients often lack the necessary support within the community. Through the A4i app and portal, individuals with severe mental illness who are either transitioning back to the community from inpatient care or outpatients using community services, will now have another layer of support and connectivity with their care team to help them thrive. Article content 'This milestone partnership between the Waypoint Centre for Mental Health Care and A4i demonstrates the real-world benefits that can be achieved when digital innovation is pursued and critical technologies are deployed within the life sciences sector,' said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. 'By investing in organizations like OBIO ®, our government is committed to strengthening this leading industry, ensuring that we not only build on our past successes, but lay a foundation for competitiveness and economic growth for generations to come. We congratulate Waypoint, A4i, and OBIO ® on this collaboration and look forward to seeing their combined expertise support patients and care teams across Ontario.' Article content 'We're thrilled to harness technology to enhance our clients' recovery, with A4i offering timely resources and peer support to complement our team's care,' commented Kevin Young, Vice-President Medical Affairs and Chief of Staff at Waypoint. Article content 'The adoption of A4i's technology at Waypoint is a game changer for individuals with complex behavioural and mental health conditions, providing them with the tools and support they need to be empowered in their healthcare decisions and stay engaged with their healthcare team,' said Dr. Maura Campbell, President and CEO of OBIO ®. 'We are delighted to have facilitated the evaluation and adoption of this technology through our EAHN™ and LSCTC programs.' Article content ABOUT: Article content A4i Article content A4i (App4Independence) is a validated mobile app and clinical portal that supports individuals with schizophrenia and complex mental illnesses like opioid use disorder. A4i offers self-management features such as AI-driven wellness detection, adherence escalations, secure peer engagement, and a patented auditory hallucination detector. Designed to scale clinical decision support and peer support, A4i predicts relapse and risk. Founded in 2018 as a spin-off from the Centre for Addiction and Mental Health (CAMH), Canada's leading mental health and addiction research hospital, A4i was co-created with MEMOTEXT Corp. to empower recovery journeys for individuals facing challenges such as psychosis-related illness and opioid use disorders. Article content Article content Article content or contact Amos Adler CEO, A4i, Article content amos@ Article content Waypoint is a fully accredited academic and teaching hospital providing specialty mental health and addiction services and geriatric services for Simcoe County, Muskoka and central Ontario, as well as forensic mental health services for all of Ontario. As a regional provider of specialized services, the hospital has an extensive range of acute and longer-term psychiatric inpatient, outpatient and community-based program to meet the diverse needs of people of all ages, cultures and identities. Through our work and our Waypoint Research Institute, our team of forward-thinking experts provides leadership to the broader healthcare system. We harness partnership, innovation and research to advance understanding of mental health and addiction and improve lives locally and around the world. Article content ® Article content , a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, evaluates new technologies through its Early Adopter Health Network (EAHN™), supported by the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and implements successful solutions using critical technologies through its Life Sciences Critical Technologies and Commercialization (LSCTC) Centre of Excellence, supported by the Government of Ontario. OBIO Article content ® Article content on Article content LinkedIn Article content and Article content X Article content . Article content Article content Article content Article content Article content Contacts Article content MEDIA CONTACTS: Article content A4i (App4Independence) Article content Article content Amos Adler Article content Article content CEO Article content Article content amos@ Article content Waypoint Centre for Mental Health Care Article content Travis Mealing Article content Article content Communications Officer Article content Article content mediainquiry@ Article content OBIO ® Article content Article content Doriane Rey Article content Article content Article content Article content
Yahoo
20-02-2025
- Business
- Yahoo
Orchestra BioMed to Present at Upcoming Investor Conferences
NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, 'Orchestra BioMed' or the 'Company'), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences. Details on the Company's presence at these conferences are shown below. Presentations Format: Corporate Presentation Date: March 3, 2025Time: 2:30 PM ETWebcast: Format: Fireside ChatDate: March 13, 2025Time: 8:00 AM ET Live audio webcasts of the TD Cowen presentation can be accessed through the Investors section of the Company's website at An archived replay of the webcast will be available on the Company's website for 90 days following the live event. The Company will also be hosting 1x1 meetings with investors at the on February 28, 2025. About Orchestra BioMedOrchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit and follow us on LinkedIn . References to Websites and Social Media Platforms References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release. Investor Contact:Jeremy FefferLifeSci AdvisorsJfeffer@ Media Contact:Kelsey Kirk-EllisOrchestra BioMed(484) 682-4892kkirkellis@
